Trintellix (Vortioxetine Hydrobromide) Patent Expiration, LOE Window & CMS Spending

Trintellix (Vortioxetine Hydrobromide) by Takeda: FDA Orange Book core substance LOE 2031-12-30 (last listed 2032-09-21), 0 AB generics, $602.1M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTakeda
FDA Application & PathwayN204447 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2031-12-30
Last Listed Patent or Exclusivity Date2032-09-21
Orange Book Patents (*PED Extensions)20 patents (10 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$602.1M
2024 Medicare Part D Spend$392.5M
2024 Medicaid Spend$209.6M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Takeda across sibling Meru public-data platforms.